Elligo Health Research Launches IntElligo Research Stack

Article

Applied Clinical Trials

Elligo Health Research, an integrated research organization (IRO), announced the launch of its IntElligo Research Stack clinical technology. This standards-based technology platform, which powers the System of Accelerated Research (SOAR™)model, will be launched this month as the eSource documentation tool at Elligo’s Research Ready network of study sites.

”IntElligo can be set up per the study protocol in hours and easily follows the workflow in any physician’s office,” said Jacylyn Bodmer, Elligo’s chief information officer. “We are improving data quality while relieving administrative burden at the research site and enabling more patient-centric interactions. IntElligo also facilitates remote monitoring, which results in faster source data verification and financial payments to our physicians.”

“IntElligo bridges health care and research, leveraging global industry standards from the start (CDISC PRM and CDASH), thus facilitating aggregation and tabulation into CDISC SDTM, the required format for regulatory eSubmissions to the FDA and Japan’s PMDA,” added Rebecca Kush, Ph.D., Elligo’s chief scientific officer.

In addition, the technology provides real-time management financial management, reports, analytics across research sites, and achieves true eSource. Furthermore, it creates the opportunity to transform research through the SOAR model - expanding patient access and driving efficiency by enabling direct data from source to submission.

“By uniting our Goes Direct approach with this technology and infrastructure to support physicians, we are creating the ultimate solution for clinical trial execution,” said John Potthoff, Ph.D., Elligo CEO. “The IntElligo platform will become a primary resource for our study sites, increasing the ability for physicians to provide research as a care option and enabling more patients to benefit.”

Learn more at www.elligodirect.com

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.